Document:

SECURITIES PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (“Agreement”) is made as of this 1st day of November, 2012 by and among Novelos
Therapeutics, Inc., a Delaware corporation (the “Company”) and Renova Industries Ltd., a
company incorporated and registered under the laws of the Bahamas (“Renova”).  

 

Recitals:

 

A.         The Company desires,
pursuant to this Agreement, to raise the Investment Amount (as defined below) through the issuance and sale, in the aggregate,
of the following to Renova (the “Private Placement”): (i) 2,000,000 shares (the “Common Shares”)
of Common Stock, par value $0.00001 per share (the “Common Stock”); (ii) 90-day warrants to acquire an
additional 2,000,000 shares of Common Stock with an exercise price of $1.00 per share; and (iii) 5-year warrants to acquire an
additional 1,000,000 shares of Common Stock with an exercise price of $1.25 per share, such warrants to be in the form of Exhibit
A annexed hereto and made a part hereof (such warrants, collectively, the “Warrants”);

 

B.         Renova desires
to purchase from the Company, and the Company desires to issue and sell to Renova, upon the terms and conditions stated in this
Agreement, the Common Shares and the Warrants;

 

C.         Subject to the
conditions hereinafter set forth, on the Closing Date, Renova will purchase Common Shares and Warrants in the Private Placement
for an aggregate purchase price of $2,000,000.00 (the “Investment Amount”); and

 

D.         The Company
and Renova are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by
the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
(the “1933 Act”);

         

NOW, THEREFORE, in consideration
of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows:

 

1.         Definitions.
In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms
shall have the meanings set forth in this Section 1:

 

“1933 Act”
has the meaning set forth in the Recitals.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly Controls, is Controlled by, or is under common
Control with, such Person.

 

    	                                         

    	 

    
 

 

“Agreement”
has the meaning set forth in the Recitals.

 

“Business
Combination” means (i) the acquisition by a third party of a majority of the outstanding shares of capital stock
of the Company by tender or exchange offer or otherwise where such third party shall have become, directly or indirectly, the beneficial
owner (within the meaning of Rule 13d-3 under the 1934 Act) of the securities of the Company representing fifty percent (50%) or
more of the Company’s capital stock, (ii) the effectiveness of any merger of the Company with or into a third party, in which
the capital stock of the Company immediately prior to such merger represents less than fifty percent (50%) of the voting power
(without regard to the effect of any so-called “blocker provisions” of any convertible securities) of the surviving
entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such merger and (iii) the closing
of any sale of all or substantially all of the assets of the Company.

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

“Closing”
has the meaning set forth in Section 3.1.

 

“Closing
Date” has the meaning set forth in Section 3.1.

 

“Common
Stock” has the meaning set forth in the Recitals, and also includes any securities into which the Common Stock may
be reclassified.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which entitle the holder thereof to acquire
Common Stock at any time, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.

 

“Company”
has the meaning set forth in the Recitals.

 

“Company
Counsel” means Foley Hoag LLP, counsel to the Company.

 

“Company’s
Knowledge,” “Knowledge of the Company” or any like expression with respect to the Company
means the actual knowledge of the officers of the Company and the knowledge that would be reasonably expected to be known by such
individuals in the ordinary and usual course of the performance of their professional responsibilities to the Company.

 

“Company Counsel Opinion”
means a legal opinion from the Company Counsel, dated as of the Closing Date, in the form attached hereto as Exhibit B.

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

    	2

    	 

    
 

 

“Control”
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Disclosure
Schedules” has the meaning set forth in Section 4.

 

“Environmental
Laws” has the meaning set forth in Section 4.15.

 

“Indebtedness”
shall mean (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except
guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (c) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized
in accordance with United States generally accepted accounting principles.

 

“Indemnified
Person” has the meaning set forth in Section 8.3.

 

“Intellectual
Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether
or not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate
names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights
and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; (v) trade secrets, Confidential
Information and know-how (including, but not limited to, ideas, formulae, compositions, manufacturing and production processes
and techniques, research and development information, drawings, specifications, designs, business and marketing plans, and customer
and supplier lists and related information); and (vi) computer software (including, but not limited to, data, data bases and documentation).

 

“Investment
Amount” means an amount equal to $2,000,000.00.

 

“License
Agreements” has the meaning set forth in Section 4.14(b).

 

“Losses”
has the meaning set forth in Section 8.2.

 

“Material
Adverse Effect” means a material adverse effect on (i) the assets and liabilities, prospects, results of operations,
condition (financial or otherwise) or business of the Company, or (ii) the ability of the Company to issue and sell the Securities
and to perform its obligations under the Transaction Documents; provided, however, that: (A) any adverse effect that results
from general economic, business or industry conditions, the taking by the Company of any action permitted or required by the Agreement,
or the announcement or pendency of transactions contemplated hereunder, shall not, in and of itself, constitute a “Material
Adverse Effect” on the Company, and shall not be considered in determining whether there has been or would be a “Material
Adverse Effect” on the Company and (B) a decline in the Company’s stock price shall not, in and of itself, constitute
a “Material Adverse Effect” on the Company and shall not be considered in determining whether there has been or would
be a “Material Adverse Effect” on the Company.

 

    	3

    	 

    
 

 

“Material
Contract” means any contract of the Company (i) that was required to be filed as an exhibit to the SEC Filings pursuant
to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K of the 1933 Act, or (ii) the loss of which could reasonably be expected
to have a Material Adverse Effect.

 

“Preferred
Stock” means the Company’s preferred stock, par value $0.00001 per share.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Press
Release” has the meaning set forth in Section 7.4.

 

“Private
Placement” has the meaning set forth in the Recitals.

 

“Regulation
D” has the meaning set forth in the Recitals.

 

“Rule 144”
has the meaning set forth in Section 7.5.

 

“SEC”
has the meaning set forth in the Recitals.

 

“SEC Filings”
has the meaning set forth in Section 4.6.

 

“Securities”
means the Common Shares, the Warrants and the Warrant Shares.

 

“Trading
Market” means the markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question,
including without limitation: the NYSE AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, the OTC Bulletin Board or the OTCQX (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement and the Warrants.

 

“United
States” shall mean the United States of America, its territories and possessions.

 

“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.

    	4

    	 

    
 

 

“Warrants”
has the meaning set forth in the Recitals.

 

2.         Purchase
and Sale of Securities.

 

Subject to the terms
and conditions of this Agreement, including without limitation, the conditions set forth in Section 6, there shall be a
Closing at which the Company shall issue and sell, and Renova agrees to purchase, the Common Shares and the Warrants in the Private
Placement by executing a counterpart to this Agreement in exchange for the cash consideration consisting of the Investment Amount.

 

3.         Closing.

 

3.1.         Place.
The closing of the transactions contemplated by this Agreement (individually, the “Closing”; the date
of the Closing referred to as the “Closing Date”) shall take place at the offices of Company Counsel,
Seaport World Trade Center West, 155 Seaport Boulevard, Boston, MA 02210 (or remotely via the electronic exchange of documents
and signatures) or at such other location as the parties shall agree.

 

3.2.         Closing.
Simultaneously with the execution hereof, the Company shall hold the Closing. At the Closing, the Company will deliver to its transfer
agent an irrevocable direction letter instructing it to issue the Common Shares, registered in Renova’s name, and an electronic
copy of the signed Warrants exercisable for the Warrant Shares. Following such delivery, Renova shall promptly initiate a wire
transfer of immediately available funds (U.S. dollars) equal to $2,000,000.00 to be delivered to the account of the Company, account
details of which are as set forth on Schedule 3.2 affixed hereto.

 

3.3.         Delivery
of Original Common Shares and Warrants. As soon as possible after the Closing, but no later than 5 Business Days following
the Closing, the Company will deliver by overnight mail, original certificate(s) representing the Common Shares and the original
Warrants issued and sold at the Closing.

 

4.         Representations
and Warranties of the Company. The Company hereby represents and warrants to Renova on the date hereof and at the Closing,
knowing and intending their reliance hereon, that, as of the date hereof except as set forth in the schedules delivered herewith
(collectively, the “Disclosure Schedules”):

 

4.1.         Organization,
Good Standing and Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business
as now conducted and to own its properties. The Company is duly qualified to do business as a foreign corporation and is in good
standing in each jurisdiction in which the conduct of its business or its ownership or its leasing of property makes such qualification
or licensing necessary, unless the failure to so qualify would not have a Material Adverse Effect. Other than Cellectar, Inc.,
a Wisconsin corporation, the Company has no subsidiaries.

 

    	5

    	 

    
 

 

4.2.         Authorization.
The Company has full power and authority and has taken all requisite action on the part of the Company, its officers, directors
and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) authorization of
the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation
for issuance) and delivery of the Securities as of the Closing Date The Transaction Documents constitute the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their respective terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’
rights generally.

 

4.3.         Capitalization.

 

(a)         Schedule
4.3 sets forth (i) the authorized capital stock of the Company on the date hereof, (ii) the number of shares of capital stock
issued and outstanding, (iii) the number of shares of capital stock issuable pursuant to the Company’s stock plans, and (iv)
the number of shares of capital stock issuable and reserved for issuance pursuant to securities (other than the Securities) exercisable
for, or convertible into or exchangeable for any shares of capital stock of the Company. All of the issued and outstanding shares
of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of
pre-emptive rights and were issued in full compliance with applicable law and any rights of third parties. No Person is entitled
to pre-emptive or similar statutory or contractual rights with respect to any securities of the Company. Except as described on
Schedule 4.3, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements
of any character under which the Company is or may be obligated to issue any equity securities of any kind and, except as contemplated
by this Agreement, the Company is not currently in negotiations for the issuance of any equity securities of any kind. Except as
described on Schedule 4.3, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements
or other agreements of any kind among the Company and any of its security holders relating to the securities of the Company. Except
as described on Schedule 4.3, the Company has not granted any Person the right to require the Company to register any of
its securities under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company
for its own account or for the account of any other Person.

 

(b)         Schedule
4.3 sets forth a true and complete table setting forth the pro forma capitalization of the Company on a fully diluted basis
giving effect to (i) the issuance of the Common Shares and Warrants at the Closing, (ii) any adjustments in other securities resulting
from the issuance of the Common Shares and Warrants at the Closing, and (iii) the exercise or conversion of all outstanding securities.
Except as described on Schedule 4.3, the issuance and sale of the Securities hereunder will not obligate the Company to
issue shares of Common Stock or other securities to any other Person (other than Renova) and will not result in the adjustment
of the exercise, conversion, exchange or reset price of any outstanding security.

 

(c)         Except
as set forth on Schedule 4.3, the Company does not have outstanding stockholder purchase rights or any similar arrangement
in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events.

 

    	6

    	 

    
 

 

(d)         Except
as set forth on Schedule 4.3, there are no stockholder rights plans, or similar plan or arrangement in effect, including
those under which Renova would be considered an “acquiring person” or under which Renova would be deemed to trigger
provisions by virtue of Renova’s receipt of Securities under the Transaction Documents.

 

4.4.         Valid
Issuance. The Common Shares have been duly and validly authorized as of the relevant Closing Date, and, when issued to Renova
in accordance with the terms of this Agreement, will be validly issued, fully paid and nonassessable and shall be free and clear
of all liens, claims, encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents
or imposed by applicable securities laws. The Warrants have been duly and validly authorized and, upon the due exercise of each
Warrant, the applicable Warrant Shares will be validly issued, fully paid and non-assessable, and shall be free and clear of all
liens, claims, encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed
by applicable securities laws. The Company has reserved a sufficient number of shares of Common Stock for issuance upon exercise
of the Warrants outstanding as of the Closing.

 

4.5.         Consents.
The execution, delivery and performance by the Company of the Transaction Documents and
the offer, issuance and sale of the Securities require no consent of, action by or in respect of, or filing with, any Person, governmental
body, agency, or official other than those consents set forth on Schedule 4.5 and filings that have been made pursuant to
applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company
undertakes to file within the applicable time periods. The Company has taken all action necessary to exempt (i) the issuance and
sale of the Securities, (ii) the issuance of the Warrant Shares issuable upon due exercise of each Warrant, and (iii) the other
transactions contemplated by the Transaction Documents from the provisions of any anti-takeover, business combination or control
share law or statute binding on the Company or to which the Company or any of its assets and properties may be subject or any provision
of the Company’s Certificate of Incorporation, Bylaws or any stockholder rights agreement that is or could become applicable
to Renova, as a result of the transactions contemplated hereby, including without limitation, the issuance of the Securities and
the ownership, disposition or voting of the Securities by Renova or the exercise of any right granted to Renova pursuant to this
Agreement or the other Transaction Documents.

 

4.6.         Delivery
of SEC Filings; Business. Copies of the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December
31, 2011, the Company’s quarterly reports on Form 10-Q for the
quarters ended March 31, 2012 and June 30, 2012, and reports on Form 8-K filed by the Company from January 1, 2012 through the
Closing (collectively, the “SEC Filings”) are available on EDGAR. The SEC Filings are the only
filings required of the Company pursuant to the 1934 Act for such period. The Company is engaged only in the business described
in the SEC Filings and the SEC Filings contain a complete and accurate description in all material respects of the business of
the Company.

 

4.7.         No
Material Adverse Change. Except as contemplated herein or identified and described on Schedule 4.7(a), since June 30,
2012, there has not been:

 

(a)         any change
in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected in the financial
statements included in the SEC Filings, except for changes in the ordinary course of business which have not and could not reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate;

 

    	7

    	 

    
 

 

(b)         any declaration
or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the Company, or
any redemption or repurchase of any securities of the Company;

 

(c)         any material
damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company or its Subsidiaries;

 

(d)         any waiver,
not in the ordinary course of business, by the Company of a material right or of a material debt owed to it;

 

(e)         any satisfaction
or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business
and which is not material to the assets, properties, financial condition, operating results, prospects or business of the Company;

 

(f)         any change
or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any Material Contract or arrangement
by which the Company is bound or to which any of its assets or properties is subject;

 

(g)         any material
labor difficulties or labor union organizing activities with respect to employees of the Company;

 

(h)         any transaction
entered into by the Company other than in the ordinary course of business;

 

(i)         loss of
the services of any key employee, or material change in the composition or duties of the senior management of the Company;

 

(j)         the loss
or threatened loss of any customer which has had or could reasonably be expected to have a Material Adverse Effect; or

 

(k)         any other
event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

4.8.         SEC
Filings.         At the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements
of the 1934 Act and did not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company
has not registered any of its securities with the SEC under Sections 12(b) or 12(g) of the 1934 Act and is not required to do so
by any regulations of any Trading Market, 1934 Act or otherwise by SEC regulations. The Company is required to file reports pursuant
to Section 15(d) of the 1934 Act. The Company is not (with or without the lapse of time or the giving of notice, or both) in breach
or default of any Material Contract and, to the Company’s Knowledge, no other party to any Material Contract is (with or
without the lapse of time or the giving of notice, or both) in breach or default of any Material Contract. The Company has not
received any notice of the intention of any party to terminate any Material Contract.

 

    	8

    	 

    
 

 

4.9.         No
Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions
of, or constitute a default under (i) the Company’s Certificate of Incorporation or Bylaws, both as in effect on the date
hereof (true and accurate copies of which have been provided to Renova before the date hereof), or (ii)(a) any statute, rule, regulation
or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or any of its
respective assets or properties, or (b) except as set forth on Schedule 4.9, any agreement or instrument to which the Company
is a party or by which it is bound or to which any of its assets or properties is subject.          

 

4.10.         Tax
Matters. The Company has timely prepared and filed all tax returns required to have been filed by it with all appropriate governmental
agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of the
Company in respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments
against the Company nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes, penalties or interest
for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material
to the Company. All taxes and other assessments and levies that the Company is required to withhold or to collect for payment have
been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or
claims pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or properties. Except
as described on Schedule 4.10, there are no outstanding tax sharing agreements or other such arrangements between the Company
and any other corporation or entity. The Company is not presently undergoing any audit by a taxing authority, nor has it waived
or extended any statute of limitations at the request of any taxing authority.

 

4.11.         Title
to Properties. Except as disclosed in the SEC Filings or as set forth on Schedule 4.11, the Company has good and marketable
title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects
that would materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof
by the Company; and except as disclosed in the SEC Filings, the Company holds any leased real or personal property under valid
and enforceable leases with no exceptions that would materially interfere with the use made or currently planned to be made thereof
by the Company.

 

4.12.         Certificates,
Authorities and Permits. The Company possesses adequate certificates, authorities or permits issued by appropriate governmental
agencies or bodies necessary to conduct the business now operated by it, and the Company has not received any notice of proceedings
relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company,
could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.

 

    	9

    	 

    
 

 

4.13.         No
Labor Disputes. No material labor dispute with the employees of the Company exists or, to the Company’s Knowledge, is
imminent.

 

4.14.         Intellectual
Property.

 

(a)         All Intellectual
Property of the Company is currently in compliance with all legal requirements (including timely filings, proofs and payments of
fees) and is valid and enforceable. Except as listed on Schedule 4.14(a), no Intellectual Property of the Company which
is necessary for the conduct of Company’s businesses as currently conducted or as currently proposed to be conducted has
been or is now involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no such action is threatened.
Except as listed on Schedule 4.14(a), no patent of the Company has been or is now involved in any interference, reissue,
re-examination or opposition proceeding.

 

(b)         All of
the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are necessary for
the conduct of the Company’s business as currently conducted or as currently proposed to be conducted to which the Company
is a party or by which any of its assets are bound (other than  generally commercially available, non-custom, off-the-shelf
software application programs having a retail acquisition price of less than $25,000 per license) (collectively, “License
Agreements”) are valid and binding obligations of the Company and, to the Company’s Knowledge, the other parties
thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’
rights generally, and there exists no event or condition which will result in a material violation or breach of or constitute (with
or without due notice or lapse of time or both) a default by the Company under any such License Agreement.

 

(c)         The Company
owns or has the valid right to use all of the Intellectual Property that is necessary for the conduct of the Company’s business
as currently conducted or as currently proposed to be conducted, free and clear of all liens, encumbrances, adverse claims or obligations
to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary
course of the Company’s business. The Company has a valid and enforceable right to use all third-party Intellectual Property
and Confidential Information used or held for use in the respective business of the Company as currently conducted or as currently
proposed to be conducted.

 

(d)         To the
Company’s Knowledge, the conduct of the Company’s business as currently conducted and as currently proposed to be conducted
does not and will not infringe any Intellectual Property rights of any third party or any confidentiality obligation owed to a
third party. To the Company’s Knowledge, the Intellectual Property and Confidential Information of the Company which are
necessary for the conduct of Company’s business as currently conducted or as currently proposed to be conducted are not being
infringed by any third party. Except as set forth on Schedule 4.14(d), there is no litigation or order pending or outstanding
or, to the Company’s Knowledge, threatened or imminent, that seeks to limit or challenge or that concerns the ownership,
use, validity or enforceability of any Intellectual Property or Confidential Information of the Company and the Company’s
use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there
is no valid basis for the same.

 

    	10

    	 

    
 

 

(e)         The consummation
of the transactions contemplated hereby will not result in the alteration, loss, impairment of or restriction on the Company’s
ownership or right to use any of the Intellectual Property or Confidential Information which is necessary for the conduct of the
Company’s respective business as currently conducted or as currently proposed to be conducted.

 

(f)         To the
Company’s Knowledge, all software owned by the Company, and, to the Company’s Knowledge, all software licensed from
third parties by the Company, (i) is free from any material defect, bug, virus, or programming, design or documentation error;
(ii) operates and runs in a reasonable and efficient business manner; and (iii) conforms in all material respects to the specifications
and purposes thereof.

 

(g)         The Company
has taken reasonable steps to protect its rights in its Intellectual Property and Confidential Information. Each employee, consultant
and contractor who has had access to Confidential Information which is necessary for the conduct of Company’s business as
currently conducted or as currently proposed to be conducted has executed an agreement to maintain the confidentiality of such
Confidential Information and has executed appropriate agreements that are substantially consistent with the Company’s standard
forms therefor. To the Company’s Knowledge, there has been no material disclosure of any of the Company’s Confidential
Information to any third party without the Company’s consent.

 

4.15.         Environmental
Matters. The Company (i) is not in violation of any statute, rule, regulation, decision or order of any governmental agency
or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating
to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental
Laws”), (ii) neither owns nor operates any real property contaminated with any substance that is subject to any Environmental
Laws, (iii) is not liable for any off-site disposal or contamination pursuant to any Environmental Laws, and (iv) is not subject
to any claim relating to any Environmental Laws; which violation, contamination, liability or claim has had or could reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the Company’s
Knowledge, threatened investigation that might lead to such a claim.

 

4.16.         Litigation.
Except as set forth in Section 4.16, there are no pending actions, suits or proceedings against or affecting the Company
or any of its properties; and to the Company’s Knowledge, no such actions, suits or proceedings are threatened or contemplated.

 

4.17.         Financial
Statements. The financial statements of the Company included in the SEC Filings fairly present the consolidated financial position
of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, and such
financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a
consistent basis. Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the
date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those which, individually or in the
aggregate, have not had or could not reasonably be expected to have a Material Adverse Effect.

 

    	11

    	 

    
 

 

4.18.         Insurance
Coverage. The Company maintains in full force and effect insurance coverage and the Company reasonably believes such insurance
coverage is adequate. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
on terms consistent with market for the Company’s lines of business.

 

4.19.         Brokers
and Finders. Except as disclosed in Schedule 4.19, no Person will have, as a result of the transactions contemplated
by this Agreement, any valid right, interest or claim against or upon the Company or Renova for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.

 

4.20.         No
Directed Selling Efforts or General Solicitation. Neither the Company nor any Affiliate, nor any Person acting on its behalf
has conducted any “general solicitation” or “general advertising” (as those terms are used in Regulation
D) in connection with the offer or sale of any of the Securities.

 

4.21.         No
Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the 1933
Act, which would require the registration of any such securities under the 1933 Act or under the rules and regulations of the Trading
Market on which any of the securities of the company are listed or designated, including circumstances that would adversely affect
reliance by the Company on Section 4(2) of the 1933 Act for the exemption from the registration requirements imposed under Section
5 of the 1933 Act for the transactions contemplated hereby or would require such registration the 1933 Act.

 

4.22.         Private
Placement. Subject to the accuracy of the representations and warranties of Renova contained in Section 5 hereof, the
offer and sale of the Securities to Renova as contemplated hereby is exempt from the registration requirements of the 1933 Act.

 

4.23.         Questionable
Payments. Neither the Company nor, to the Company’s Knowledge, any of its current or former stockholders,
directors, officers, employees, agents or other Persons acting on its behalf, has on behalf of the Company or in connection with
the Company’s business: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses
relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from
corporate funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any
false or fictitious entries on the books and records of the Company; (e) made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment of any nature; or (f) violated in any material respect any provision of the Foreign Corrupt
Practices Act of 1977, as amended.

 

    	12

    	 

    
 

 

4.24.         Transactions
with Affiliates. Except as set forth on Schedule 4.24, none of the officers or directors of the Company and, to the Company’s
Knowledge, none of the employees of the Company is presently a party to any transaction, or presently contemplated transaction,
with the Company (other than for services as employees, officers and directors) that would be required to be disclosed pursuant
to Item 404 of Regulation S-K promulgated under the 1933 Act.

 

4.25.         Trading
Compliance. The Common Stock is quoted on the OTCQX trading platform and the Company has taken no action designed to, or which
to the Company’s Knowledge is likely to have the effect of, causing the Common Stock not to continue to be quoted on the
OTCQX. No order ceasing or suspending trading in any securities of the Company or prohibiting the issuance and/or sale of the Securities
is in effect and no proceedings for such purpose are pending or threatened. The Company is in compliance with all OTCQX rules and
regulations in effect as of the Closing necessary to ensure that the Common Stock is authorized to be quoted on the OTCQX.

 

4.26.         Acknowledgment
Regarding Renova’s Purchase of Securities. The Company acknowledges that Renova is not acting as a financial advisor
or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby
and any advice given by Renova or any of their respective representatives or agents in connection with this Agreement and the transactions
contemplated hereby is merely incidental to Renova’s purchase of the Securities.

 

4.27.         Sarbanes-Oxley;
Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 that
are applicable to it as of the Closing. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with United States general accepted
accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and
procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures
to ensure that material information relating to the Company, is made known to the certifying officers by others within those entities,
particularly during the period in which the Company’s most recently filed periodic report under the 1934 Act, as the case
may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls
and procedures as of the date prior to the filing date of the most recently filed periodic report under the 1934 Act (such date,
the “Evaluation Date”). The Company presented in its most recently filed periodic report under the 1934 Act
the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls
(as such term is defined in Item 307(b) of Regulation S-K under the 1934 Act) or, to the Knowledge of the Company, in other factors
that could significantly affect the Company’s internal controls.

 

    	13

    	 

    
 

 

4.28.         Solvency.
Based on the financial condition of the Company as of the Closing after giving effect to the receipt by the Company of the proceeds
from the sale of the Securities hereunder, the Company’s assets do not constitute unreasonably small capital to carry on
its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into
account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital
availability thereof. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into
account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no present intention to, nor
does it have a present belief that it will need to, file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction. Schedule 4.28 sets forth all outstanding secured and unsecured Indebtedness of the Company, or
for which the Company has commitments. The Company is not in default with respect to any Indebtedness.

 

4.29.         Investment
Company. The Company is not, and immediately after receipt of payment for the Securities will not be, an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.

 

5.         Representations
and Warranties of Renova. Renova hereby represents and warrants to the Company on and as of the Closing, knowing and intending
that the Company rely thereon, that:

 

5.1.         Authorization.
The execution, delivery and performance by Renova of the Transaction Documents to which Renova is a party have been duly authorized
and will each constitute the valid and legally binding obligation of Renova, enforceable against Renova in accordance with their
respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general
applicability, relating to or affecting creditors’ rights generally.

 

5.2.         Purchase
Entirely for Own Account. The Securities to be received by Renova hereunder will be acquired for Renova’s own account,
not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and
Renova has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the
1933 Act. Renova is not a registered broker dealer or an entity engaged in the business of being a broker dealer.

 

5.3.         Investment
Experience. Renova acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and
has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the
investment contemplated hereby. Renova has significant experience in making private investments, similar to the purchase of the
Securities hereunder.

 

5.4.         Disclosure
of Information. Renova has had an opportunity to receive all additional information related to the Company requested by it
and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of
the offering of the Securities. Renova acknowledges receipt of copies of and its satisfactory review of the SEC Filings. Neither
such inquiries nor any other due diligence investigation conducted by Renova shall modify, amend or affect Renova’s right
to rely on the Company’s representations and warranties contained in this Agreement.

 

    	14

    	 

    
 

 

5.5.         Restricted
Securities. Renova understands that the Securities are characterized as “restricted securities” under the U.S.
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and
that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain
limited circumstances.

 

5.6.          Legends.

 

(a)         It is understood
that, except as provided below, certificates evidencing such Securities may bear the following or any similar legend:

 

“THE SECURITIES
REPRESENTED HEREBY MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT
OF 1933, AS AMENDED, OR (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY
BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933 OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS.”

 

(b)         If required
by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such state authority.

 

(c)         Notwithstanding
any restrictions on transfer set forth in this Section 5.6, Renova may sell, transfer, assign, pledge or otherwise dispose
of the Securities, in whole or in part, to any of its Associated Companies or any third party subject to (i) compliance with all
applicable securities laws and the conditions set forth in this Section 5.6 and (ii) the delivery to the Company of such
documentation as may be reasonably requested by the Company and reasonably necessary for the Company to obtain a legal opinion
that such disposition may lawfully be made without registration under the Securities Act.

 

5.7.         Accredited
Investor. Renova is an “accredited investor” as defined in Rule 501(a) of Regulation D.

 

5.8.         No
General Solicitation. Renova did not learn of the investment in the Securities as a result of any “general advertising”
or “general solicitation” as those terms are contemplated in Regulation D.

 

5.9.         Brokers
and Finders. Other than as disclosed on Schedule 4.19, no Person will have, as a result of the transactions contemplated
by this Agreement, any valid right, interest or claim against or upon the Company or Renova for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of Renova.

 

    	15

    	 

    
 

 

6.         Conditions
to Closing.

 

6.1.         Conditions
to Renova’s Obligations. The obligation of Renova to purchase the Securities at the Closing is subject to the fulfillment
to Renova’s satisfaction, on or prior to the Closing, of the following conditions, any of which may be waived in writing
by Renova:

 

(a)         The representations
and warranties made by the Company, in Article 4 as of the Closing that are qualified as to materiality shall be true and
correct in all respects, and those not so qualified shall be true and correct in all material respects as of the Closing;

 

(b)         The Company
shall have performed in all material respects all obligations herein required to be performed or observed by it on or prior to
the Closing;

 

(c)         The Company
shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary or appropriate
for consummation of the purchase and sale of the Securities being issued and sold at the Closing, and all of which shall be and
remain so long as necessary in full force and effect;

 

(d)         The Common
Shares to be issued at the Closing shall have been duly and validly authorized and, when issued to Renova in accordance with the
terms of this Agreement, shall be validly issued, fully paid and nonassessable, and shall be free and clear of all liens, claims,
encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable
securities laws;

 

(e)         As of the
Closing, no judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding
shall have been instituted by any governmental authority, or self-regulatory organization enjoining or preventing the consummation
of the transactions contemplated hereby or in the other Transaction Documents;

 

(f)         The
Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial
Officer, dated as of the Closing, certifying to the fulfillment of the conditions specified in subsections (a), (b), (c), (d),
(f) and (k) of this Section 6.1;

 

(g)         The Company
shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing, certifying the
resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the
other Transaction Documents and the issuance and sale of the Securities, certifying the current versions of the Certificate of
Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents
and all related documents on behalf of the Company;

 

(h)         Renova
shall have received a Company Counsel Opinion with respect to the Securities to be issued at the Closing; and

 

    	16

    	 

    
 

 

(i)         As of the
Closing, no stop order or suspension of trading shall have been imposed by any Person with respect to public trading in the Common
Stock.

 

6.2.         Conditions
to Obligations of the Company. The Company’s obligation to sell and issue the Securities at the Closing is subject to
the fulfillment to the satisfaction by the Company on or prior to the Closing of the following conditions, any of which may be
waived in writing by the Company.

 

(a)         The representations
and warranties made by Renova in Section 5 hereof that are qualified as to materiality shall be true and correct in all
respects, and those not so qualified shall be true and correct in all material respects, at all times prior to and as of the Closing;

 

(b)         Renova
shall have performed in all material respects all obligations herein required to be performed or observed by it on or prior to
the Closing;

 

(c)         Renova
shall have delivered the Investment Amount;

 

(d)         No judgment,
writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or
judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted
by any governmental authority, or self-regulatory organization enjoining or preventing the consummation of the transactions contemplated
hereby or in the other Transaction Documents; and

 

(e)         Renova
shall have delivered to the Company a completed Purchaser Questionnaire in the form attached hereto as Exhibit C.

 

7.         Covenants
and Agreements of the Company.

 

7.1.         Reservation
of Common Stock. The Company shall at all times reserve and keep available out of its authorized but unissued shares of Common
Stock, solely for the purpose of providing for the exercise of each Warrant issued to Renova, such number of shares of Common Stock
as shall from time to time equal 100% of the number of shares sufficient to permit the exercise of each Warrant issued pursuant
to this Agreement in accordance with their respective terms, without regard to any exercise limitations contained therein.

 

7.2.         Trading.
The Company shall promptly, following the Closing, take all actions necessary and continue to take all actions necessary as contemplated
in this Agreement or otherwise to ensure that the Common Shares and the Warrant Shares are authorized to be quoted on the OTCQX,
including the timely filing of all SEC Filings as required under Section 7.7.

 

7.3.         Use
of Proceeds. The Company will use the proceeds from the sale of the Securities to fund activities associated with establishing
the capacity to manufacture the Company’s clinical-stage compound I-124-CLR1404 (LIGHT) in the Company’s facility in
Madison, WI, substantially in accordance with the schedule of activities set forth in Schedule 7.3 (the “Project”).
Furthermore, if Renova exercises all or a portion of the Warrants, the proceeds to the Company from such exercises will be used
to fund the Project, to the extent the Investment Amount is not sufficient to fund the completion of the Project. Any proceeds
from Warrant exercises not required to fund the completion of the Project will be used for general corporate purposes.

 

    	17

    	 

    
 

 

7.4.         Press
Release; Form 8-K Filing. On or before 9:00 a.m., New York City time, on the first Business Day following the date of this
Agreement, the Company shall issue a press release, which shall have been reviewed and approved by Renova, announcing the transactions
contemplated by the Transaction Documents (the “Press Release”). The Company will file a Current Report
on Form 8-K (the “8-K”) with the SEC describing the terms of the Transaction Documents (and including
as exhibits to such Current Report on Form 8-K the material Transaction Documents (including, without limitation, this Agreement
and the form of Warrant)). The 8-K will be filed within four (4) Business Days of signing of this Agreement.

 

7.5.         Furnishing
of Information. As long as Renova owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the 1934 Act. As long as Renova owns Common Shares, the Warrant or the Warrant Shares, if the Company is not required to file reports
pursuant to such laws, it will prepare and furnish to the Investors and make publicly available in accordance with Rule 144(c)
promulgated by the SEC pursuant to the 1933 Act, as such Rule may be amended from time to time, such information as is required
for the Investors to sell the Common Shares and Warrant Shares under Rule 144 promulgated by the SEC pursuant to the 1933 Act,
as such Rule may be amended from time to time (“Rule 144”). The Company further covenants that it will
take such further action as Renova may reasonably request, all to the extent required from time to time to enable Renova to sell
the Common Shares and Warrant Shares without registration under the 1933 Act and without the volume restrictions imposed by Rule
144.

 

7.6.         Integration.
Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf shall, directly or indirectly, make
any offers or sales of any Company security or solicit any offers to buy any security, under circumstances that would adversely
affect reliance by the Company on Section 4(2) of the 1933 Act for the exemption from the registration requirements imposed under
Section 5 of the 1933 Act for the transactions contemplated hereby or would require such registration the 1933 Act.

 

7.7.         SEC
Filings. The Company shall timely file all SEC Filings and ensure that they comply as to form in all material respects with
the requirements of the 1934 Act and do not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the light of the circumstances under which they are made, not misleading.

 

7.8.         Financial
Statements. The financial statements of the Company included in each SEC Filing shall fairly present the consolidated financial
position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown,
and such financial statements shall be prepared in conformity with United States generally accepted accounting principles applied
on a consistent basis. Except as set forth in the financial statements of the Company included in the SEC Filings, the Company
has not incurred any liabilities, contingent or otherwise, except those which, individually or in the aggregate, have not had,
or could not reasonably be expected to have a Material Adverse Effect.

 

    	18

    	 

    
 

 

7.9.         Compliance
with Applicable Law. The Company shall use its best efforts (i) to comply in all material respects with all statutes, laws,
regulations, rules, judgments, orders and decrees of all governmental entities applicable to it that relate to its business, (ii)
to maintain all permits that are required in order to permit it to carry on its business as it is presently conducted and (iii)
to comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002.

 

7.10.         Cooperation.
The Company agrees to use commercially reasonable efforts to cooperate with Renova in selling its Securities pursuant to Rule 144.

 

7.11.         Exemption
from Investment Company Act of 1940. The Company shall conduct its business in a manner so that it will not become subject
to the Investment Company Act of 1940.

 

8.         Survival
and Indemnification.

 

8.1.         Survival.
All representations, warranties, covenants and agreements contained in this Agreement shall be deemed to be representations, warranties,
covenants and agreements as of the date hereof and shall survive the Closing Dates until the third anniversary thereof; provided,
however, that the provisions contained in: (a) Sections 4.4, 8.1, 8.2, 8.3, and Article 9
hereof shall survive indefinitely; and (b) Sections 4.10 and 4.15 shall survive until 90 days after the applicable
statute of limitations.

 

8.2.         Indemnification.
The Company agrees to indemnify and hold harmless, Renova and its Associated Companies and the directors, officers, employees and
agents of Renova and its Associated Companies, from and against any and all losses, claims, damages, liabilities and expenses (including
without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing
or defending any action, claim or proceeding, pending or threatened and the costs of enforcement hereof) (collectively, “Losses”)
to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by, or
to be performed on the part of, the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person.

 

8.3.         Conduct
of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 8.2, such Indemnified Person shall promptly
notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably
satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding,
any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention
of such counsel; (ii) in the reasonable judgment of counsel to such Indemnified Person (A) representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interests between them, or (B) the Company shall have
failed to promptly assume the defense of such proceeding. The Company shall not be liable for any settlement of any proceeding
effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned, but if settled
with such consent, or if there be a final judgment for the plaintiff, the Company shall indemnify and hold harmless such Indemnified
Person from and against any Losses by reason of such settlement or judgment. Without the prior written consent of the Indemnified
Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of
any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could
have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified
Person from all liability arising out of such proceeding.

 

    	19

    	 

    
 

 

9.         Miscellaneous.

 

9.1.         Successors
and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company and Renova;
provided, however, that Renova may assign its rights and delegate its duties hereunder in whole or in part to a third
party acquiring some or all of its Securities in a private transaction with the prior written consent of the Company, after notice
duly given by Renova to the Company, such consent not to be reasonably withheld by the Company and that no such assignment or obligation
shall affect the obligations of Renova hereunder; and provided further that Renova may assign its rights and delegate
its duties hereunder in whole or in part to one or more Affiliates of Renova in a private transaction without the prior written
consent of the Company, after notice duly given by Renova to the Company and that no such assignment or obligation shall affect
the obligations of Renova hereunder. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Except for provisions of this Agreement expressly to the contrary, nothing in
this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.

 

9.2.         Counterparts;
Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed
an original.

 

9.3.         Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

9.4.         Notices.
Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (ii) if given by telex or telecopier, then such notice shall be deemed given upon receipt of confirmation of complete
transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the
recipient or (B) three (3) Business Days after such notice is deposited in first class mail, postage prepaid, and (iv) if given
by a nationally recognized overnight air courier, then such notice shall be deemed given one (1) Business Day after delivery to
such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as
such party may designate by ten (10) days’ advance written notice to the other party:

 

    	20

    	 

    
 

 

If to the Company:

 

Novelos Therapeutics, Inc.

One Gateway Center, Suite 504

Newton, MA 02458

USA

Attention: Chief Executive Officer

Fax: (617) 964-6331

 

With a copy to:

 

Foley Hoag LLP

Seaport World Trade Center West

155 Seaport Boulevard

Boston, MA 02210

USA

Attn: Paul Bork

Fax: (617) 832-7000

 

If to Renova:

 

Renova Industries Ltd.

2nd Terrace West Centreville

P.O. Box N-7755

Nassau, Bahamas

Attn: Carl Stadelhofer

 

9.5.         Amendments
and Waivers. This Agreement shall not be amended and the observance of any term of this Agreement shall not be waived (either
generally or in a particular instance and either retroactively or prospectively) without the prior written consent of the Company
and Renova.  Any amendment or waiver effected in accordance with this Section 9.6 shall be binding upon each holder
of any Securities purchased under this Agreement at the time outstanding, each future holder of all such Securities, and the Company.

 

9.6.         Publicity.
Except as provided in Section 9.8, no public release or announcement concerning the transactions contemplated hereby shall
be issued by the Company or Renova without the prior consent of the Company (in the case of a release or announcement by Renova)
or Renova (in the case of a release or announcement by the Company) (which consents shall not be unreasonably delayed or withheld),
except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange
or securities market on which the Securities are then listed and trading, in which case the Company or Renova, as the case may
be, shall allow the other, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release
or announcement in advance of such issuance.

 

    	21

    	 

    
 

 

9.7.         Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable
in any respect.

 

9.8.         Entire
Agreement. This Agreement, including the Exhibits and Disclosure Schedules, and the other Transaction Documents constitute
the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof. Prior drafts
or versions of this Agreement shall not be used to interpret this Agreement.

 

9.9.         Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

9.10.         Governing
Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of the
State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the
exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for
the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this
Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may
be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this
Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding
and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought
in any such court has been brought in an inconvenient forum. THE COMPANY AND RENOVA HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATING TO OR ARISING OUT OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY.

 

[Signature Page Follows]

    	22

    	 

    

Signature Page

 

IN WITNESS WHEREOF,
each of the undersigned has executed this Securities Purchase Agreement or caused its duly authorized officers to execute this
Securities Purchase Agreement as of the date first above written.

 

	 	NOVELOS THERAPEUTICS, INC.
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Harry S. Palmin	 
	 	Name:	Harry S. Palmin	 
	 	Title:	President and CEO	 

 

 

 

 

	 	RENOVA INDUSTRIES LTD.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Carl Stadelhofer	 
	 	Name:	Carl Stadelhofer	 
	 	Title:	Director	 

 

 

 

    	 

    	 

    

EXHIBIT A         

 

NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE
UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
AND APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR (II) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.

 

 

 

CLASS ___ COMMON STOCK PURCHASE WARRANT

 

__________

 

	Warrant Shares: _______	Initial Exercise Date: _______, 2012

 

 

 

THIS CLASS ___ COMMON STOCK PURCHASE WARRANT
(the “Warrant”) certifies that, for value received, Renova Industries Ltd. or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on ______________1
(the “Termination Date”) but not thereafter, to subscribe for and purchase from Novelos Therapeutics, Inc.,
a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant
Shares”) of the common stock, par value $0.00001 per share, of the Company (the “Common Stock”). The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.         Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the “Purchase Agreement”), dated November 1, 2012, between the Company and Renova.

 

Section 2.         Exercise.

 

 

 

 

1
Insert 5 year anniversary of closing for Class A and 90th day following closing for Class B warrants.

    	 

    	 

    
 

 

a)         Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as
it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company)
of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within three (3) Trading Days following the date
of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice
of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is required in connection with the applicable Notice of Exercise. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within
one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. “Trading
Day” and “Trading Market” shall have the meaning ascribed to such terms in the Purchase Agreement.

 

b)         Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $_____2,
subject to adjustment hereunder (the “Exercise Price”).

 

c)         Cashless
Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:

 

(A) = the VWAP on the Trading Day
immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as
set forth in the applicable Notice of Exercise;

 

(B) = the Exercise Price of this
Warrant, as adjusted hereunder; and

 

(X) = the number of Warrant
Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.

 

 

 

2
Insert $1.25 for Class A and $1.00 for Class B

    	 

    	 

    
 

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for the Trading Day immediately preceding
such date on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the OTC Bulletin Board is not a Trading
Market, the volume weighted average price of the Common Stock for the Trading Day immediately preceding such date on the OTC Bulletin
Board, (c) if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Company and reasonably acceptable to the Holder, the fees and expenses of which
shall be paid by the Company.

 

d)         Mechanics
of Exercise.

 

i.         Delivery
of Warrant Shares Upon Exercise. The Company shall use best efforts to cause the Warrant Shares purchased hereunder to be transmitted
by the Company’s transfer agent by physical delivery to the address specified by the Holder in the Notice of Exercise by
the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender
of this Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise,
if permitted) (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been
issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such
shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by
cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to
the issuance of such shares, having been paid.

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly Controls, is Controlled by, or is under common
Control with, such Person.

 

“Control” means
the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise.

 

“Person” means
an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

    	 

    	 

    
 

 

ii.         Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.         Rescission
Rights. If the Company fails to cause the Company’s transfer agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.         Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Company’s transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	 

    	 

    
 

 

v.         No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.         Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that in the event Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all of the Company’s transfer agent fees required for same-day processing of any Notice of
Exercise.

 

vii.         Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

Section 3.         Certain Adjustments.

 

a)         Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

    	 

    	 

    
 

 

b)         Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time
the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c)         Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	 

    	 

    
 

 

d)         Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder
of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction.
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice
as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3
transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a Fundamental Transaction involving a person or entity
not traded on a national securities exchange, including, but not limited to, the Nasdaq Global Select Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, the Company or any Successor Entity (as defined below) shall, at the Holder’s option,
exercisable at any time concurrently with, or within 30 days after the consummation of the Fundamental Transaction, purchase
this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining
unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction. “Black Scholes Value”
means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function
on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an
expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the
Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per
share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash
consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The Company shall cause
any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance
with the provisions of this Section 3(d) pursuant to written agreements prior to such Fundamental Transaction and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of
this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer
instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been
named as the Company herein.

 

    	 

    	 

    
 

 

e)         Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)         Notice
to Holder.

 

i.         Adjustments.
Whenever the Exercise Price or the number or type of securities for which this Warrant is exercisable are adjusted pursuant to
any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth such adjusted Exercise Price
or such number or type securities, as applicable, and setting forth a brief statement of the facts requiring such adjustment.

 

ii.         Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company
shall simultaneously file such notice with the Securities and Exchange Commission pursuant to a Current Report on Form 8-K. The
Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    	 

    	 

    
 

 

Section 4.         Transfer of Warrant.

 

a)         Transferability.
This Warrant and the rights hereunder may be transferred only pursuant to a registration statement filed under the Securities Act,
or an exemption from such registration. Subject to such restrictions, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Warrant Shares without having a new Warrant issued.

 

b)         New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

c)         Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

d)         Compliance
with the Securities Act. The Company may cause the legend set forth on the first page of this Warrant to be set forth on each
Warrant or similar legend on any security issued or issuable upon exercise of this Warrant, unless counsel for the Corporation
is of the opinion as to any such security that such legend is unnecessary.

 

Section 5.         Miscellaneous.

 

a)         No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)         Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

    	 

    	 

    
 

 

c)         Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.

 

d)         Authorized
Shares.

 

The Company covenants that, during
the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing
stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will
at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon
such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    	 

    	 

    
 

 

Before taking any action which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

e)         Governing
Law; Jurisdiction. This Warrant shall be governed by, and construed in accordance with, the internal laws of the State of New
York, without reference to the choice of law provisions thereof. The Company and, by accepting this Warrant, the Holder, each irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding
may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this
Warrant. The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any such court
in any such suit, action or proceeding and to the laying of venue in such court. The Company and, by accepting this Warrant, the
Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts
and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient
forum. THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATING
TO OR ARISING OUT OF THIS WARRANT AND THE TRANSACTIONS CONTEMPLATED HEREBY.

 

f)         Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

g)         Notices.
Unless otherwise provided, any notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively
given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii)
if given by telex or facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii)
if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B)
three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one day after delivery to such carrier. All notices shall be addressed
as follows: if to the Holder, at its address as set forth in the Company’s books and records and, if to the Company, at Novelos
Therapeutics, Inc., One Gateway Center, Suite 504, Newton, MA 02458, Attention: Chief Executive Officer, Fax: (617) 964-6331, or
at such other address as the Holder or the Company, as applicable, may designate by ten days’ advance written notice to the
other.

 

    	 

    	 

    
 

 

h)         Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

i)         Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

j)         Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.

 

k)         Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

l)         Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

 

********************

 

(Signature Page Follows)

    	 

    	 

    
 

 

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

	 	
        novelos therapeutics,
        inc.

         

         
	 
	 	By:	 	 
	 	 	Name: Harry S. Palmin	 
	 	
         
	
        Title: President and CEO

        
	 

 

         

 

    	 

    	 

    
 

NOTICE OF EXERCISE

 

To:         novelos therapeutics,
inc. 

 

(1)         The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)         Payment shall
take the form of (check applicable box):

 

[ ] in lawful
money of the United States; or

 

[ ] [if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)         Please issue said
Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity:
	 
	Signature of Authorized Signatory of Investing Entity:
	 
	Name of Authorized Signatory:
	 
	Title of Authorized Signatory:
	 
	Date:
	 

 

 

 

    	 

    	 

    

 

 

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

 

 

FOR VALUE RECEIVED, [____] all
of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

 

_______________________________________________ whose address
is

 

_______________________________________________________________.

 

 

 

_______________________________________________________________

 

Dated: ______________, _______

 

 

	 	Holder’s Signature:	_____________________________
	 	 	 
	 	Holder’s Address:	_____________________________
	 	 	 
	 		_____________________________

 

 

 

Signature Guaranteed: ___________________________________________

 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.

 

 

    	 

    	 

    

 

 

EXHIBIT B

	November _, 2012	 	
        Seaport West

        155 Seaport Boulevard

        Boston, MA 02210-2600

         

        617 832 1000 main

        617 832 7000 fax

	 	 	 

 

 

	
        Renova Industries, Ltd.

        2nd Terrace West Centreville

        P.O. Box N-7755

        Nassau, Bahamas

        Attn: Carl Stadelhofer

         
	 

 

Re:         Securities Purchase
Agreement

 

Ladies and Gentlemen:

 

We have acted as counsel for Novelos Therapeutics,
Inc., a Delaware corporation (the “Company”), in connection with the execution and delivery of the Securities Purchase
Agreement by and between the Company and the Purchaser party thereto of even date herewith (the “Agreement”). All terms
used herein have the meanings defined for them in the Agreement unless otherwise defined herein.

 

This opinion is furnished to you in connection with the Closing
of the issuance and sale of 2,000,000 units, consisting of 2,000,000 shares (the “Shares”) of the Company’s common
stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase an aggregate of 3,000,000 shares
of Common Stock (the “Warrants”) on the date hereof pursuant to the Agreement. The shares of Common Stock issuable
upon exercise of the warrants are referred to herein as the “Warrant Shares.”

 

The opinions expressed herein are subject
to the following assumptions, limitations, qualifications and exceptions:

 

(a)         We have made such legal and factual examinations
and inquiries as we have deemed advisable or necessary for the purpose of rendering this opinion. We have relied as to factual
matters on the representations and warranties contained in the Agreement and the related agreements and documents delivered in
connection with the Closing by the Company. We have assumed the completeness and accuracy of all factual matters described in such
representations and warranties and have not made any independent review or investigation of factual matters in connection with
the preparation of this opinion.

 

(b)         In rendering the opinions expressed below,
we have examined originals or copies of: (i) the Agreement, (ii) the Warrants, (iii) the Company’s Certificate of Incorporation,
as amended through the date hereof (the “Certificate of Incorporation”) and (iv) the Company’s By-laws, as in
effect on the date hereof (the “By-laws”), and we have examined, among other things, originals or copies of such corporate
records of the Company, certificates of public officials and such other documents and questions of law that we consider necessary
or advisable for the purpose of rendering this opinion. In such examination we have assumed the genuineness of all signatures or
original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to original
documents of all copies submitted to us as copies thereof, the legal capacity of natural persons, and the due execution and delivery
of all documents (except as to due execution and delivery by the Company) where due execution and delivery are a prerequisite to
the effectiveness thereof.

 

    	 

    	 

    
 

 

(c)          For purposes of this opinion,
we have assumed that you have all requisite power and authority, and have taken any and all necessary corporate action, to execute
and deliver the Agreement, and that the representations and warranties made by the Purchaser in the Agreement and pursuant thereto
are true and correct as of the date hereof.

 

(d)         Our opinion is based upon
our knowledge of the facts as of the date hereof and assumes no event will take place in the future which would affect the opinions
set forth herein other than future events contemplated by the Agreement. We assume no duty to communicate with you with respect
to any change in law or facts which comes to our attention hereafter.

 

(e)         In rendering the opinion
in paragraph 1 below with respect to legal existence and good standing of the Company in the State of Delaware, we have relied
solely upon a certificate of the Secretary of State of Delaware and we express such opinion as of the date of such certificate.
We express no opinion as to the tax good standing of the Company in any jurisdiction.

 

We have made such examination of Massachusetts
law, United States federal law, and the Delaware General Corporation Law (the “DGCL”) as we have deemed necessary for
the purpose of this opinion. In rendering opinions concerning the DGCL, we have, with your consent, relied exclusively upon a review
of published statutes. We express no opinion herein as to the laws of any jurisdiction other than The Commonwealth of Massachusetts,
the federal laws of the United States of America and the DGCL. Except for our opinion in paragraph 7 below, we
express no opinion herein with respect to compliance by the Company with any United States federal securities laws or state or
securities or “blue sky” laws, including in each case any securities anti-fraud laws. We
note that the Agreement and the Warrants purport to be governed by the laws of the State of New York. To the extent that any of
the opinions expressed herein relate to or may require application of any law of the State of New York, we have assumed, with your
permission, that the applicable New York law is substantively the same in all material respects as Massachusetts law.

 

The opinions expressed herein are qualified
to the extent that (1) the enforceability of any provisions of the Agreement or any instrument delivered or any right granted thereunder,
including the Warrants, may be subject to or affected by any bankruptcy, reorganization, insolvency, fraudulent conveyance, moratorium
or other similar law of general application relating to or affecting the rights or remedies of creditors generally, which law may
be in effect from time to time; (2) the remedy of specific performance or any other equitable remedy may be unavailable or may
be withheld as a matter of judicial discretion; (3) equitable principles and principles of public policy may be applied in construing
or enforcing the provisions of the Agreement or of any other agreement, instrument or document; and (4) the enforceability, validity
or binding effect of any remedial provision of the Agreement may be limited by applicable law which may limit particular rights
and remedies. In addition, the opinions expressed herein are subject to the qualification that the enforcement of any of your rights
is in all cases subject to your implied duty of good faith and fair dealing.

 

    	 

    	 

    
 

 

We express no opinion herein as to the validity
or enforceability of any provision of the Agreement or any other instrument or document including the Warrants to the extent that
such provision purports to (1) constitute a waiver by the Company of any constitutional right, or of any statutory right except
where advance waiver is expressly permitted by the relevant statute; (2) require the Company to indemnify or to hold harmless you
or any other person or entity from the consequences of any negligent or other wrongful act or omission of you or such other person
or entity; (3) provide for indemnification or contribution by the Company in connection with the Agreement, the transactions contemplated
thereby or otherwise to the extent such indemnification or contribution may be limited by applicable laws or as a matter of public
policy; or (4) constitute a waiver of any right to a hearing on or adjudication of any issue or the right to trial by jury.

 

In connection with the preparation of this
opinion, we have not made any independent review or investigation of any court or agency docket or other litigation papers or of
any judgment, order, decree, ruling or decision of any governmental commission, bureau or other regulatory authority or agency
applying primarily to the Company, nor have we made any independent investigation as to the existence of any actions, suits, investigations
or proceedings, if any, pending or threatened against the Company, any Purchaser or any other person or entity.

 

As used in the opinions expressed throughout,
the phrase “to our knowledge” means the actual knowledge of any of the lawyers within our firm who have worked on the
transactions contemplated by the Agreement, without any special investigation with respect to the matter as to which any such opinion
is so qualified.

 

Based upon and subject to the foregoing, we are of the opinion
that:

 

1.         The Company is a corporation validly
existing and in good standing under the laws of the State of Delaware. The Company has all requisite corporate power and authority
to own and operate its properties and assets and to carry on its business as now conducted and as proposed to be conducted (all
as described in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2011).

 

2.         The Company has all requisite power
and authority to (i) execute, deliver and perform the Agreement and the Warrants, (ii) to issue, sell and deliver the Shares and
the Warrants pursuant to the Agreement, and, upon due exercise of the Warrants, the Warrant Shares and (iii) to carry out and perform
its obligations under, and to consummate the transactions contemplated by, the Agreement and the Warrants.

 

3.         All corporate action on the part of
the Company, its directors and its stockholders necessary for the authorization, execution and delivery by the Company of the Agreement
and the Warrants, the authorization, issuance, sale and delivery of the Shares and the Warrants pursuant to the Agreement, the
issuance and delivery of the Warrant Shares upon due exercise of the Warrants and the consummation by the Company of the transactions
contemplated by the Agreement and the Warrants has been duly taken. The Agreement and the Warrants have been duly and validly executed
and delivered by the Company and constitute the legal, valid and binding obligation of the Company, enforceable against the Company
in accordance with their terms.

 

4.         The authorized capital stock of the
Company consists of 150,000,000 shares of Common Stock and 7,000 shares of Preferred Stock. The Shares have been duly authorized
for issuance and, when issued, sold and delivered in accordance with the terms and for the consideration set forth in the Agreement,
will be validly issued, fully paid and nonassessable. The Warrant Shares have been duly and validly authorized and reserved for
issuance, and when issued upon the exercise of the Warrants in accordance with the terms therein, will be validly issued, fully
paid and nonassessable, and free of any preemptive or similar rights arising under the DGCL or the Certificate of Incorporation
or By-laws.

 

 

    	 

    	 

    

 

5.         The execution, delivery and performance
by the Company of, and the compliance by the Company with the terms of, the Agreement and the issuance, sale and delivery of the
Shares, the Warrants and the Warrant Shares pursuant to the Agreement do not (a) conflict with or result in a violation of any
provision of law, rule or regulation applicable to the Company or of the Certificate of Incorporation or By-laws, (b) conflict
with any order, writ, judgment or decree specifically naming the Company and known to us or (c) result in a breach of or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or result in or permit the termination
or modification of, any agreement included as an exhibit to the Registration Statement under Item 601(b)(10) of Regulation S-K
promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

 

6.         In connection
with the execution, delivery and performance by the Company of the Agreement, or the offer, sale, issuance or delivery of the Shares,
the Warrants and the Warrant Shares or the consummation of the transactions contemplated thereby, no consent, license, permit,
waiver, approval or authorization of, or designation, declaration, registration or filing with, any Massachusetts or federal governmental
authority or pursuant to the DGCL, is required (other than filings required to be made after the Closing under applicable
United States federal securities laws).

 

7.         Assuming
the accuracy of your representations in Section 5 of the Agreement, the offer, issuance and sale of the Shares and Warrants to
you at the Closing pursuant to the Agreement are, subject to the making of applicable exemptive
filings, exempt from registration under the Securities Act.

 

8.         The Company is not, and after the
consummation of the transactions contemplated by the Agreement shall not be, an Investment Company within the meaning of the Investment
Company Act of 1940, as amended.

 

9.         We are not representing the Company
in any pending litigation in which the Company is a named defendant that challenges the validity or enforceability of, or seeks
to enjoin the performance of, the Agreement or the Warrants.

 

This opinion shall be interpreted in accordance
with the Legal Opinions Principles issued by the Committee on Legal Opinions of the American Bar Association’s Business Law
Section as published in 53 Business Lawyer 831 (May 1998).

 

This opinion is furnished to the Purchaser
solely for their benefit in connection with the transactions described above and, except as otherwise expressly set forth herein,
may not be relied upon by any other person or for any other purpose without our prior written consent.

 

 

	 	Very truly yours,
	 	 	 	 
	 	FOLEY HOAG LLP
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	 	 
	 	 	A Partner	 

 

    	 

    	 

    

 

EXHIBIT C

 

NOVELOS THERAPEUTICS, INC.

 

INSTRUCTIONS FOR COMPLETION

OF PROSPECTIVE INVESTOR QUESTIONNAIRE

 

Prospective investors in Novelos Therapeutics,
Inc., a Delaware corporation (the “Company”) must complete and sign the attached Prospective Investor Questionnaire.
The purpose of the Questionnaire is to determine whether you, or the entity on whose behalf you are completing this Questionnaire,
meet qualify as an “accredited investor” as defined in rule 501(a) promulgated under the United States Securities Act
of 1933, as amended (the “Securities Act”). The offering will be a registered direct offering under the Securities
Act, but has not been, and will not be, qualified under the securities laws of your state, and the securities involved in this
offering are being sold in reliance upon an exemption from the registration or qualification requirements thereof, which reliance
is based on the information contained in your response to this Questionnaire. This Questionnaire is not an offer to sell, or a
solicitation of any offer to buy, any securities of the Company.

 

Please complete, as thoroughly as possible,
sign and date this Questionnaire, and deliver it to the Company. If an entity is the potential investor, the term “you”
in the Questionnaire refers to the entity rather than the individual completing this Questionnaire.

 

Your answers will be kept strictly confidential,
except to the extent disclosure may be required under any federal or state laws. However, each person who agrees to invest in the
Company agrees that the Company may present this Questionnaire or a copy hereof to its attorneys or such other parties as the Company,
in its sole discretion, deems appropriate to assure itself that the proposed offer and sale of the securities of the Company will
not result in a violation of the securities or “blue sky” laws of your state.

 

 

*         *         *

    	 

    	 

    

 

PROSPECTIVE INVESTOR QUESTIONNAIRE

 

THIS QUESTIONNAIRE MUST BE COMPLETED AND DELIVERED TO NOVELOS
THERAPEUTICS, INC. (THE “COMPANY”) BY YOU AS A PROSPECTIVE INVESTOR IN THE COMPANY.

 

Please print or type:

 

		1.	General Information

 

Legal Name of Potential Investor: __________________________________________________

 

____________________________________________________________________________

 

Business Address: ______________________________________________________________

 

_____________________________________________________________________________         

 

Business Telephone: ____________________________

 

SSN or EIN: ____________________________

 

If applicable:

 

Home Address: ________________________________________________________________

 

______________________________________________________________________________

 

Date of Birth: _______________________ Home Telephone: ____________________________

 

Spouse’s Name: ________________________________________________________________

 

		2.	Qualification as Accredited Investor

 

a.          Are you a natural person whose current net worth or joint
net worth with your spouse, excluding the value of your primary residence, exceeds $1,000,000?

 

Yes_____         No_____

 

For purposes of this net worth calculation, you may exclude
the amount of indebtedness secured by your primary residence up to the amount of the value of your primary residence. Any indebtedness
secured by your primary residence in excess of the value of your primary residence should, however, be treated as a liability and
deducted from your net worth.

 

    	 

    	 

    
 

 

b.          Are you a natural people who had an individual income
in excess of $200,000 in each of the two most recent years or joint income with your spouse in each of those years in excess of
$300,000 and do you reasonably expect to achieve the same income levels in the present year?

 

Yes_____         No_____

 

c.          Are you a director or executive officer of the Company?

 

Yes_____         No_____

 

d.          Are you or, if applicable, the entity on whose behalf
you are completing this Questionnaire:

 

(i) a bank as defined in Section 3(a)(2)
of the Securities Act or a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities
Act, whether acting in its individual or fiduciary capacity?

 

Yes_____         No_____

 

(ii) a broker or dealer registered pursuant
to Section 15 of the United States Securities Exchange Act of 1934?

 

Yes_____         No_____

 

(iii) an insurance company as defined in
Section 2(a)(13) of the Securities Act?

 

Yes_____         No_____

 

(iv) an investment company registered under
the United States Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of such Act?

 

Yes_____         No_____

 

(v) a Small Business Investment Company
licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the United States Small Business Investment Act
of 1958?

 

Yes_____         No_____

 

 

    	 

    	 

    

         (vi) a plan established and maintained
by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit
of its employees which has total assets in excess of $5,000,000?

 

Yes_____         No_____

 

(vii) an employee benefit plan within the
meaning of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which
all investment decisions are made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings
and loan association, insurance company, or registered investment adviser?

 

Yes_____         No_____

 

(viii) an employee benefit plan within the
meaning of ERISA which has total assets in excess of $5,000,000?

 

Yes_____         No_____

 

(ix) a self-directed employee benefit plan
within the meaning of ERISA, with investment decisions made solely by persons that are accredited investors as set forth in this
question 2?

 

Yes_____         No_____

 

(x) a private business development company
as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940?

 

Yes_____         No_____

 

(xi) an organization described in Section
501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or similar business trust, or a partnership, with total
assets in excess of $5,000,000?

 

Yes_____         No_____

 

If your answer to the preceding question
was “yes,” was the entity on whose behalf you are completing this Questionnaire formed for the purpose of investing
in the Company?

 

Yes_____         No_____

 

If so, how many persons are beneficial owners
of the equity securities or equity interests of such entity?

 

____________

 

(xii) a trust with total assets in excess
of $5,000,000 whose purchase is directed by a person who has such knowledge and experience in financial and business matters that
he or she is capable of evaluating the merits and risks of the prospective investment in the Company?

 

Yes_____         No_____

 

If your answer to the preceding question
was “yes,” was the entity on whose behalf you are completing this Questionnaire formed for the purpose of investing
in the Company?

 

Yes_____         No_____

 

If so, how many persons are beneficial owners
of the equity securities or equity interests of such entity?

 

____________

 

e.          Are you completing this Questionnaire on behalf of an
entity in which all of the equity owners are accredited investors within the meaning of Rule 501 promulgated under the Securities
Act who are within one of the categories of accredited investors described in one of the paragraphs of this question 2?

 

Yes_____         No_____

 

[signature page follows]

 

    	 

    	 

    

The foregoing statements are true, accurate
and complete to the best of the undersigned’s information and belief, and the undersigned hereby agrees promptly to notify
and supply corrective information to the Company if, prior to the consummation of the undersigned’s investment in the Company,
any of such information becomes inaccurate or incomplete.

 

For Execution by Natural Person(s)

 

 

	_______________________________	____________________________________
	Signature of Prospective Investor	Please Print Name

 

Executed at____________________________________________________________________

          City                                                            State

 

on this ______ day of ______________, 2012.

 

 

For Execution by Corporate, Partnership
or Trust Prospective Investor

 

                            ____________ 

Name of Corporation, Partnership or Trust (Please Print)

 

	By:	____________________________	 
	 	 	 
	Title:	____________________________	 
	 	 	 
	________________________________	 

Signature of person making the

investment decision on behalf of the entity.

 

Executed at ______________________________________________________________         

City                                                          State

 

on this ______ day of ______________, 2012.

 

 

    	 

    	 

    

Disclosure
Schedules 

TO

SECURITIES PURCHASE AGREEMENT

 

Dated as of November 1, 2012

Among

 

Novelos Therapeutics, Inc. and Renova
Industries Ltd.

 

 

These Disclosure Schedules, dated as of
November 1, 2012, are being delivered by Novelos Therapeutics, Inc., a Delaware corporation (the “Company”),
pursuant to the Securities Purchase Agreement, dated as of November 1, 2012 (the “Agreement”), by and among
the Company and Renova Industries Ltd. Any capitalized terms used in these Disclosure Schedules but not otherwise defined therein
shall be defined as set forth in the Agreement.

 

These Disclosure
Schedules are arranged in sections that correspond to the sections of the Agreement. With respect to any section hereof corresponding
to a section of Article IV of the Agreement (i) each such section hereof qualifies the correspondingly numbered representation
or warranty to the extent specified herein, and (ii) any disclosure set forth with respect to a particular section of Article IV
shall be deemed to be disclosed in reference to such other sections of Article IV to the extent it is reasonably clear from
a reading of the disclosure that such disclosure is applicable to such other sections or subsections.

 

The Company may, at its option, include
in these Disclosure Schedules items that are not material in order to avoid any misunderstanding, and such inclusion, or any references
to dollar amounts, shall not be deemed to be an acknowledgement or representation that such items are material, to establish any
standard of materiality or to define further the meaning of such terms for purposes of the Agreement. No disclosure in these Disclosure
Schedules relating to a possible breach or violation of any Material Contract, law or order shall be construed as an admission
or indication that breach or violation exists or has actually occurred.

 

The insertion of headings in these Disclosure
Schedules is for convenience of reference only and shall not affect or be utilized in construing or interpreting the Agreement.
All references in these Disclosure Schedules to any “Section” or “Article” are to the corresponding Section
or Article, as applicable, of the Agreement unless otherwise specified.

 

    	 

    	 

    

Schedule 3.2

 

	Bank:	Citizens Bank RI
	Bank Address:	1 Citizens Drive, Riverside, RI 02915, USA
	 	617-527-8059
	Account Name:	Novelos Therapeutics, Inc.
	Account Address:	One Gateway Center, Suite 504
	 	Newton, MA 02458, USA
	ABA (Routing) #:	011500120
	Swift Code:	CTZIUS33
	Account #:	1310914637

 

Schedule 4.3 

 

Capitalization

 

4.3(a)(i) At the Closing Date authorized capital stock of the
Company consists of 150,000,000 shares of $.00001 par value common stock and 7,000 shares of preferred stock.

 

4.3(a)(ii) At the Closing Date there are 44,397,997 shares of
common stock outstanding and no shares of preferred stock outstanding.

 

4.3(a)(iii) At the Closing Date there are 4,675,754 shares of
common stock issuable pursuant to the Company’s stock plans.

 

4.3(a)(iv) Immediately prior to Closing, the following shares
are reserved for future issuance upon exercise of stock options or warrants:

 

	Stock Options	 	 	4,675,754	 
	Warrants	 	 	18,512,459	 
	 	 	 	 	 
	Total shares reserved for future issuance	 	 	23,188,213	 

 

4.3(a)

 

Immediately prior to Closing, the Company has the following
outstanding warrants:

 

	 
 
Offering
	 	 
 
Outstanding
	 	 	 
Exercise
                                                                                                                                                                                                                                      
 Price
	 	 	 
 
Expiration
                                                                                                                                                                                                                                                                                                                                  Date

	 	 	 	 	 	 	 	 	 
	2012 Registered Direct	 	 	2,981,440	 	 	$	1.25	 	 	June 2017
	2011 Underwritten Offering	 	 	9,248,334	 	 	$	0.60	 	 	December 2016
	April 2011 PIPE	 	 	6,058,811	 	 	$	0.75	 	 	March 2016
	2010 registered offering warrants	 	 	27,310	 	 	$	0.60	 	 	July 2015
	Preferred incentive warrants	 	 	105,040	 	 	$	16.07	 	 	July 2015
	Series E - Purdue	 	 	60,330	 	 	$	99.45	 	 	December 2015
	Purdue - common financing	 	 	31,194	 	 	$	100.98	 	 	December 2015
	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	18,512,459	 	 	 	 	 	 	 

 

    	 

    	 

    
 

 

The following is a listing of the Company’s documents
relating to the rights of stockholders, or holders of securities exercisable for the Company’s common stock as related to
the Company’s outstanding common stock, stock options and warrants described above:

 

	 	 	EDGAR Reference
	Description	 	Form	 	Filing Date	 	
        Exhibit

        No.

	 	 	 	 	 	 	 
	
        2000 Stock Option and Incentive Plan

         
	 	SB-2	 	November 16, 2005	 	10.2
	
        Form of 2004 non-plan non-qualified stock option

         
	 	SB-2	 	November 16, 2005	 	10.3
	
        Form of non-plan non-qualified stock option used

        from February to May 2005

         
	 	SB-2	 	November 16, 2005	 	10.4
	
        Form of non-plan non-qualified stock option used after
        May 2005

         
	 	SB-2	 	November 16, 2005	 	10.5
	
        2006 Stock Incentive Plan, as amended

         
	 	S-1/A	 	December 7, 2009	 	10.16

 

	
        Form of Incentive Stock Option under Novelos Therapeutics,
        Inc.’s 2006 Stock Incentive Plan*

         
	 	8-K	 	December 15, 2006	 	10.1
	
        Form of Non-Statutory Stock Option under Novelos Therapeutics,
        Inc.’s 2006 Stock Incentive Plan

         
	 	8-K	 	December 15, 2006	 	10.2
	
        Form of Non-Statutory Director Stock Option under
        Novelos Therapeutics, Inc.’s 2006 Stock Incentive Plan*

         
	 	8-K	 	December 15, 2006	 	10.3
	
        Common Stock Purchase Warrant dated February 11, 2009

         
	 	8-K	 	February 18, 2009	 	4.2
	
        Securities Purchase Agreement dated August 25, 2009

         
	 	S-1	 	September 15, 2009	 	10.41
	
        Common Stock Purchase Warrant dated August 25,2009

         
	 	S-1	 	September 15, 2009	 	10.43
	
        Form of Common Stock Purchase Warrant to be issued
        pursuant to the Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock
        dated July 6, 2010

         
	 	S-1A	 	July 7, 2010	 	10.53
	
        Form of Securities Purchase Agreement dated July 21, 2010

         

        
	 	8-K	 	July 22, 2010	 	10.1

 

    	 

    	 

    
 

 

	Form of Common stock Purchase Warrant dated April 8, 2011	 	8-K	 	April, 11 2011	 	4.3
	 	 	 	 	 	 	 
	Securities Purchase Agreement dated April 8, 2011	 	8-K	 	April 11, 2011	 	10.1
	 	 	 	 	 	 	 
	Form of Warrant dated December 6, 2011	 	S-1/A	 	November 9, 2011	 	4.2
	 	 	 	 	 	 	 
	Form of Securities Purchase Agreement dated June 7, 2012	 	8-K	 	June 11, 2012	 	10.1
	 	 	 	 	 	 	 
	Form of Common Stock Purchase Warrant dated June 13, 2012	 	8-K	 	June 11, 2012	 	4.1
	 	 	 	 	 	 	 
	Form of Amendment to Class B Common Stock Purchase Warrant	 	8-K	 	September 12, 2012	 	10.1
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

    	 

    	 

    

 

Schedule 4.3 (continued)

4.3(b)

 

The following table sets forth the pro forma capitalization
of the Company on a fully diluted basis giving effect to (i) the issuance of the Common Stock and Warrants at the time of the Closing,
(ii) any adjustments in other securities resulting from the issuance of the Common Stock and Warrants at the time of the Closing,
and (iii) the exercise or conversion of all outstanding securities.

 

	Pro Forma NVLT - Capital Structure Post-Private Placement	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	Common Stock Equivalents	 	Exer./Conv.  Price	 	 Expiration
	 	 	 	 	 	 	 	 
	Common stock outstanding	 	      46,397,997	 	 	 	 
	 	 	 	 	 	 	 	 
	Warrants/Options:	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	2012 Private Placement - Renova	 	        2,000,000	 	$1.00	 	January 2013
	 	2012 Private Placement - Renova	 	        1,000,000	 	$1.25	 	October 2017
	 	2012 Registered Direct - Class A	 	        2,981,440	 	$1.25	 	June 2017
	 	2011 Underwritten Offering	 	        9,248,334	 	$0.60	 	December 2016
	 	April 2011 PIPE	 	        6,058,811	 	$0.75	 	March 2016
	 	2010 registered offering warrants	 	             27,310	 	$0.60	 	July 2015
	 	Stock Options	 	        4,639,516	 	$0.45-$1.88	 	May2021;Dec 2021
	 	 	 	 	 	 	 	 
	 	Novelos legacy options and warrants	 	           232,802	 	$62.21	 	2015 through 2019
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	FULLY DILUTED	 	      72,586,210	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

 

4.3(c) Arrangements that provide rights for any Person to purchase
an equity interest in the Company consist of the stock options and warrants, previously disclosed in schedule 4.3(a).

 

 

4.3(d) – None.

 

    	 

    	 

    
 

Schedule 4.5

 

Consents 

 

None.

 

 

 

 

    	 

    	 

    

Schedule 4.6

 

Delivery SEC Filings

 

 

We have separately furnished to the Purchaser on a confidential
basis a draft Form 10-Q with respect to the three and nine month periods ended September 30, 2012 (the “September 30,
2012 Form 10-Q”). The Company anticipates filing the September 30, 2012 Form 10-Q in substantially the form provided
to the Purchaser.

 

 

 

 

    	 

    	 

    

 

 

Schedule 4.7

 

No Material Adverse Change 

 

1.         On September 10, 2012, the Company amended
Class B Warrants to purchase 5,255,000 shares of common stock to extend the expiration date for the exercise of such warrants for
a period of thirty days; from September 11, 2012 to October 11, 2012. We filed with the Securities and Exchange Commission the
form of the Amendment to the Class B Warrants on Form 8-K on September 12, 2012. Prior to the expiration of the Class B Warrants,
the Company received warrant exercises with respect to an aggregate of 1,088,300 shares of common stock underlying the Class B
Warrants, and received aggregate cash proceeds of $1,088,300 in respect of those exercises. The balance of the Class B Warrants,
exercisable for up to 4,317,500 shares of common stock, expired. We filed a current report on Form 8-K with the Securities and
Exchange Commission on October 15, 2012 to report such matter under Item 8.01.

 

2.         On October 25, 2012,
the Company held a special meeting in lieu of annual meeting of stockholders. At the meeting, the stockholders reelected Thomas
Rockwell Mackie, James S. Manuso and John E. Niederhuber as Class I directors and approved an amendment to the 2006 Stock Incentive
Plan to increase the number of shares of common stock issuable thereunder from 7,000,000 to 10,000,000.

 

3.         To the extent appropriate, the disclosures in the September
30, 2012 Form 10-Q are incorporated by reference into this Schedule and to such other Schedules the
extent it is reasonably clear from a reading of the disclosure in the Form 10-Q that such disclosure is applicable to such
other Schedules.

 

 

    	 

    	 

    

Schedule 4.9

 

No Conflict, Breach, Violation or Default

 

None.

 

 

 

 

 

 

 

    	 

    	 

    

Schedule 4.10

 

Tax Matters 

 

 

None.

 

 

 

 

 

 

    	 

    	 

    

Schedule 4.11

 

Title to Properties 

 

The properties and assets or our wholly-owned subsidiary (Cellectar,
Inc.) are subject to the terms and provisions of a General Business Security Agreement in favor of the Wisconsin Department
of Commerce ("DOC") securing the indebtedness evidenced by Promissory Notes held by DOC in the original principal
amounts of $250,000 and $200,000 (see Schedule 4.28). 

 

 

    	 

    	 

    
 

 

Schedule 4.14 

 

Intellectual Property 

 

 

4.14(a) None.

 

4.14(d) On June 28, 2010, the Company received
a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (collectively, “BAM”) alleging that the Company
modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a
technology and assignment agreement the Company had entered into with BAM on June 20, 2000 (the “June 2000 Agreement”).
The letter references the Company’s amendment, submitted to the FDA on August 30, 2005, to its investigational new drug application
dated August 1999 as the basis for BAM’s claims and demands the transfer of all intellectual property rights concerning NOV-002
to BAM. Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least
June 25, 2010, is, to the Company’s Knowledge, still the general director and principal shareholder of ZAO BAM. The Company
believes the allegations are without merit and intends to defend vigorously against any proceedings that BAM may initiate as to
these allegations. On September 24, 2010, the Company filed a complaint in Suffolk Superior Court seeking a declaratory judgment
by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the
“April 2005 Agreement”), that Novelos’ obligations to BAM are governed solely by the April 2005 Agreement and
that the obligations of the June 2000 agreement have been performed and fully satisfied. On November 29, 2010, BAM answered the
complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011,
the Company responded to the counterclaims, denying BAM’s material allegations and stating our affirmative defenses. On June
9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos’ acquisition of Cellectar. In that
amended counterclaim, BAM alleges that the acquisition evidences Novelos’ abandonment of the technology assigned to it by
BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of
the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.
On June 15, 2011 the Company filed its response to their amended counterclaim. On August 5, 2011, the Company filed a motion for
judgment on the pleadings as to its declaratory judgment count and all counts of BAM’s amended counterclaim. The motion was
opposed by BAM and a hearing on the motion was held on September 27, 2011. On October 17, 2011, the court ruled on the Company’s
behalf for each of its declaratory judgment claims and dismissed all counts of BAM’s counterclaim. Judgment in favor of the
Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal. The Company believes the counterclaims
are without merit and intend to vigorously defend against them.

 

 

    	 

    	 

    

Schedule 4.16

 

Litigation

 

 

On June 28, 2010, the Company received a letter
from counsel to ZAO BAM and ZAO BAM Research Laboratories (collectively, “BAM”) alleging that the Company modified
the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology
and assignment agreement the Company had entered into with BAM on June 20, 2000 (the “June 2000 Agreement”). The letter
references the Company’s amendment, submitted to the FDA on August 30, 2005, to its investigational new drug application
dated August 1999 as the basis for BAM’s claims and demands the transfer of all intellectual property rights concerning NOV-002
to BAM. Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least
June 25, 2010, is, to the Company’s knowledge, still the general director and principal shareholder of ZAO BAM. The Company
believes the allegations are without merit and intends to defend vigorously against any proceedings that BAM may initiate as to
these allegations. On September 24, 2010, the Company filed a complaint in Suffolk Superior Court seeking a declaratory judgment
by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the
“April 2005 Agreement”), that Novelos’ obligations to BAM are governed solely by the April 2005 Agreement and
that the obligations of the June 2000 agreement have been performed and fully satisfied. On November 29, 2010, BAM answered the
complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011,
the Company responded to the counterclaims, denying BAM’s material allegations and stating our affirmative defenses. On June
9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos’ acquisition of Cellectar. In that
amended counterclaim, BAM alleges that the acquisition evidences Novelos’ abandonment of the technology assigned to it by
BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of
the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.
On June 15, 2011 the Company filed its response to their amended counterclaim. On August 5, 2011, the Company filed a motion for
judgment on the pleadings as to its declaratory judgment count and all counts of BAM’s amended counterclaim. The motion was
opposed by BAM and a hearing on the motion was held on September 27, 2011. On October 17, 2011, the court ruled on the Company’s
behalf for each of its declaratory judgment claims and dismissed all counts of BAM’s counterclaim. Judgment in favor of the
Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.

 

 

    	 

    	 

    

Schedule 4.19

 

Brokers and Finders

 

 

None.

 

    	 

    	 

    
 

 

Schedule 4.24

 

Affiliate Transactions

 

One of our directors, John Neis, is a managing director of Venture
Investors LLC, which beneficially owns approximately 22% of our common stock.

 

Jamey Weichert, our Chief Scientific Officer and principal founder
of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (U. Wisc.). During
the year ended December 31, 2011, we made contributions totaling $206,500 to U. Wisc. for use towards unrestricted research activities.
During the six months ended June 30, 2012, we made contributions to UW totaling $144,000 for use towards unrestricted research
activities and paid UW $144,044 for costs associated with clinical trial agreements. The Company made contributions to the UW of
$62,500 during the six months ended June 30, 2011.

 

Legacy Compounds – Transactions and Litigation

 

From its inception through 2010, Novelos was primarily engaged
in the development of certain oxidized glutathione-based compounds for application as therapies for disease, particularly cancer.
These compounds were originally developed in Russia. In June 2000, Novelos acquired commercial rights from the Russian company
(“ZAO BAM”) which owned the compounds and related Russian patents. In April 2005, Novelos acquired worldwide rights
to the compound (except for the Russian Federation) in connection with undertaking extensive development activities in an attempt
to secure US Food and Drug Administration (“FDA”) approval of the compounds as therapies. These development activities
culminated in early 2010 in an unsuccessful Phase 3 clinical trial of an oxidized glutathione compound (NOV-002) as a therapy for
non-small cell lung cancer. The principal equity owner of ZAO BAM, Mark Balazovsky, was a founder of Novelos and served as a director
until November 2006. Pursuant to the April 2005 royalty and technology transfer agreement, Novelos is required to pay ZAO BAM royalties
equal to 1.2% of net sales of oxidized glutathione products and $2,000,000 for each new oxidized glutathione drug following FDA
approval of such drug. In the absence of royalty payments, Novelos is required to pay ZAO BAM 3% of all license revenues plus 9%
of the amount by which Novelos’ license revenues exceed its total expenses. In 2008, Novelos paid $15,000 to ZAO BAM representing
3% of payment under a foreign license agreement. Novelos is also obligated to pay Oxford Group, Ltd., or its assignees, a royalty
in the amount of 0.8% of our net sales of oxidized glutathione-based products. Simyon Palmin, a founder of Novelos, a director
until August 15, 2008 and the father of Harry Palmin, is president of Oxford Group. At this time, Novelos does not expect to devote
any substantial resources to the further development of its oxidized glutathione compounds.

 

 

    	 

    	 

    

 

After the disclosure of the negative outcome of the Phase 3
clinical trial in 2010, ZAO BAM claimed that Novelos modified the chemical composition of NOV-002 without prior notice to or approval
from ZAO BAM, constituting a material breach of the June 2000 technology and assignment agreement. In September 2010, Novelos filed
a complaint in Massachusetts Superior Court seeking a declaratory judgment by the court that the June 2000 agreement has been entirely
superseded by the April 2005 agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.
ZAO BAM answered the complaint and alleged counterclaims. In August 2011, Novelos filed a motion for judgment on the pleadings
as to the declaratory judgment count and all counts of ZAO BAM’s amended counterclaims. On October 17, 2011, the court ruled
in favor of Novelos on each of the declaratory judgment claims and dismissed all counts of ZAO BAM’s counterclaim. Judgment
in favor of Novelos was entered on October 20, 2011. On November 14, 2011 ZAO BAM filed a notice of appeal.

 

 

 

Schedule 4.25 

 

Trading Compliance

 

On September 18, 2012, we received a notice from OTC Markets
Group notifying us that our Investment Bank Designated Advisor for Disclosure (“DAD”) and sponsor to the OTCQX, Rodman
and Renshaw, LLC had ceased conducting its securities business and no longer qualified as a DAD. OTC Markets Group provided us
30 days to name a new DAD sponsor and has subsequently extended that period to November 17, 2012. We are currently in the process
of identifying a new investment bank sponsor and intend to name a new sponsor prior to the current deadline.

 

 

    	 

    	 

    
 

Schedule 4.28

 

Indebtedness

 

4.28(i)

 

Our wholly-owned subsidiary Cellectar, Inc. has the following
indebtedness:

 

Promissory Notes held by the Wisconsin Department of Commerce
in the original principal amounts of $250,000 and $200,000 with interest accruing at 2%.  Balance due as of September 30,
2012, including accrued interest, totaled $467,334.25. Principal and interest payments commence in May 2015 and are due in monthly
installments through April 2017.

  

The following financing statements securing obligations in material
amounts are filed with respect to Cellectar:

 

A UCC financing statement (filing #100011830417) was filed on
October 5, 2010 to secure Cellectar’s obligations to the Wisconsin Department of Commerce, as described in 4.28(i) above.
The financing statement expires on October 5, 2015.

 

 

 

    	 

    	 

    

Schedule 7.3

 

Use of Proceeds 

 

 

As of the date of this Agreement, the Project is estimated to
cost approximately $3,110,000 in the aggregate, with material components thereof estimated to be as set forth below. Both the aggregate
cost and the allocation among the components below are subject to such change as the Project may require.

 

	 	 	Estimated Cost	 
	Hot Cell	 	$	1,455,000	 
	Building/construction	 	$	1,004,000	 
	Equipment	 	$	431,800	 
	Personnel Hours	 	$	220,000	 
	 	 	 	 	 
	Total	 	$	3,110,0002012 INCENTIVE BONUS PLAN

 

 

		1.0	PURPOSE 

 

		1.1	The 2012 Incentive Bonus Plan (“Plan”) is established to incent and reward eligible
Participants (defined in Section 2.3) for performance towards achieving Business Targets and Individual Targets for the current fiscal year.

 

		2.0	DEFINITIONS

 

		2.1	“Company” means StarTek, Inc. and its operating subsidiaries.

 

		2.2	“Compensation Committee” means the compensation committee of the board of directors
of StarTek, Inc.

 

		2.3	“Participant” means the Senior Leadership Team consisting of the CEO and the direct
reports to the CEO.

 

		2.4	“Plan Year” means January 1, 2012 through December 31, 2012, inclusive.

 

		2.5	“Business Targets” are the measurements of the Company’s performance established for the Plan Year by the
Company’s executive management and Compensation Committee as described in Section 3.1(a)(i) below.

 

		2.6	“Individual Targets” are the specific and measurable goals established for a Participant for the Plan Year as described
in Section 3.1(b)(i) below.

 

		2.7	“Bonus Eligibility” is a percentage that is determined by a Participant’s position level, as shown in Appendix A.

 

		(a)	“Individual Targets Eligibility” is a percentage that is calculated by multiplying a Participant’s Bonus
Eligibility by 30% for all positions excluding CEO. There is no Individual Targets Eligibility for the CEO position.

 

		(b)	“Business Target Eligibility” is a percentage that is calculated by multiplying a Participant’s Bonus Eligibility
by the applicable Business Target percentage listed in Appendix A.

 

		2.8	“Business Targets Achievement” is the percentage by which Business Targets are achieved.

 

		2.9	“Individual Targets Achievement” is the percentage by which a Participant’s Individual Targets are achieved
as determined by the process described in Section 3.1(b).

 

		2.10	“Base Salary Earnings” is the amount of gross base salary earned by a Participant during the Plan Year for which
a bonus is calculated.

 

     

     

    
 

		3.0	MEASUREMENT CRITERION

 

		3.1	Bonus earnings under the Plan are based on two measures, Business Targets and Individual Targets. The percentage weighting
of each of the two measures for purposes of bonus calculation varies by position level per Appendix A.

 

		(a)	Business Targets

 

		(i)	The Business Targets are established for the Plan Year by the Company’s Compensation Committee. Payout for achieving
Business Targets is scaled depending on the Company’s performance during the Plan Year versus the Business Targets per the
matrix in Appendix A. Business Targets are based on revenue, free cash flow and EBITDA for the Company.

 

		(ii)	Business Target Achievement must reach at least the minimum threshold per the payout matrix in Appendix A for any payout based
on achieving Business Targets to be earned; otherwise the payout is zero.

 

		(b)	Individual Targets

 

		(i)	For each Participant, specific and measurable individual goals are established for the Plan Year (“Individual Targets”).

 

		(ii)	Payout for the Individual Targets is from 0% to 100% of the Individual Target Eligibility, depending on the percentage achievement
of Individual Targets.

 

		4.0	PAYMENT FROM THE PLAN

 

		4.1	Bonuses (if any) are earned after the 4th quarter close of the financial books. Bonuses are subject to approval
by the Company’s Compensation Committee.

 

		4.2	The amount of a Participant’s Bonus is the greater of the amounts as calculated from paragraphs (a) and (b) below. For
the avoidance of doubt, only the amount as calculated under either (a) or (b) will be paid but not both.

 

		(a)	The amount of a Participant’s Individual bonus payout, if any, equals the product of the Participant’s Base Salary
Earnings, the Participant’s Individual Target Eligibility and the Participant’s Individual Targets Achievement.

 

		(b)	The amount of a Participant’s Business Target bonus payout, if any, equals the product of the Participant’s Base
Salary Earnings, the Participant’s Individual Target Eligibility and the Participant’s Business Targets Achievement.

 

		4.3	Bonus payout, if any, is made to a Participant as a lump sum, less required payroll taxes and withholdings.

 

		4.4	In order to earn a bonus payment from the Plan, a Participant must also be in “active” status on the payroll of
the Company or one of its wholly-owned subsidiaries at the time the bonus payments are made unless otherwise provided in any written
contract with the Participant.

 

    	2 of 4

    	 

    
 

		5.0	PART-YEAR PARTICIPANT ELIGIBILITY

 

		5.1	An employee who becomes a Participant during the Plan Year may participate in the Plan on a pro rata basis. The amount of base
salary earned by such employee during the Plan year after first becoming a Participant shall be the base salary earnings used to
calculate any bonus payments.

 

		5.2	If a Participant’s employment with the Company and all of its wholly-owned subsidiaries terminates during the Plan Year
then (s)he ceases to be a Participant on the date employment is terminated. In this event, a bonus will neither be earned nor paid
unless otherwise provided in any written contract with the Participant. If a Participant changes his or her position within the
Company during the Plan year such that (s)he is no longer a Participant, then (s)he ceases to be a Participant on the date of such
change, in which case a prorated bonus would be earned through the date of such change, and be subject to Section 4.0.

 

		6.0	PROMOTIONS WITHIN THE PLAN YEAR

 

		6.1	Promotions during the Plan Year will be handled as follows:

 

		(a)	For the Business Targets and Individual Targets, bonus
calculations will be prorated based on the period of time (days) in each position level and the prorated salary for the same period
of time for each position held.

 

		7.0	PLAN APPROVALS

 

		7.1	This Plan is subject to approval by the Compensation Committee and is effective only for the Plan Year noted above. There is
no assurance that this Plan will be renewed or any similar plan will be adopted in the future.

 

		8.0	CHANGEABILITY

 

		8.1	The Compensation Committee reserves the right to change, suspend or eliminate this Plan, in whole or in part, at any time,
with or without notice to Participants.

 

 

APPROVALS:

 

	Lisa Weaver	 	Chad Carlson
	SVP & Chief Financial Officer	 	President and Chief Executive Officer

 

    	3 of 4

    	 

    
    

Appendix A

 

2012 STARTEK BONUS ELIGIBLITY MATRIX

 

	 LEVEL*	% Base	Business Targets
	 	 	FCF	EBITDA	Revenue
	Vice President	30%	10%	60%	30%
	Sr Vice President	40%	10%	60%	30%
	CFO	60%	10%	60%	30%
	CEO 	100%	10%	60%	30%

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]